{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:30:42Z","timestamp":1784712642728,"version":"3.55.0"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: This communication summarizes our single-center experience with the use of anti-IL-1 biologic response modifiers for treating autoimmune and autoinflammatory conditions in children. Methods: We outline our rationale for the off-label use of anakinra and discuss emerging treatment paradigms that necessitate further research and validation. Results: Anakinra has enabled personalized treatment, whether used as a single agent on an as-needed basis, as part of a background treatment regimen, or in combination with colchicine. Our data also highlight the significance of anakinra in treating post-infectious inflammatory diseases, demonstrating its high efficacy in novel applications such as rheumatic fever and post-viral arthritis. Canakinumab, on the other hand, has provided long-term remission. Both medications were well-tolerated, with no serious adverse effects reported. Conclusions: Based on our observations and successful outcomes, we advocate for future collaborative efforts to improve access to anti-IL-1 medications to better manage excessive and harmful inflammation in children.<\/jats:p>","DOI":"10.3390\/children11091146","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T03:36:38Z","timestamp":1727062598000},"page":"1146","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Single Center-Based Real-World Experience on Anti-IL 1 Biological Response Modifiers: A Case Series and Literature Review"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-1070","authenticated-orcid":false,"given":"Olcay","family":"Jones","sequence":"first","affiliation":[{"name":"Walter Reed National Military Medical Center, Bethesda, MD 20889, USA"},{"name":"Department Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"},{"name":"Department Rheumatology, George Washington University, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.smim.2013.10.001","article-title":"Overview of the interleukin-1 family of ligands and receptors","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","article-title":"The 2021 EULAR\/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: Cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist","volume":"81","author":"Romano","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: A cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1759720X20959575","DOI":"10.1177\/1759720X20959575","article-title":"The off-label use of anakinra in pediatric systemic autoinflammatory diseases","volume":"12","author":"Maniscalco","year":"2020","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/09546634.2020.1755417","article-title":"Off-Label studies on anakinra in dermatology: A review","volume":"33","author":"Tegtmeyer","year":"2022","journal-title":"J. Dermatolog. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1093\/milmed\/usaa508","article-title":"Multisystem Inflammatory Syndrome in Children during the COVID-19 Pandemic: A Case Report on Managing the Hyperinflammation","volume":"186","author":"Cirks","year":"2021","journal-title":"Mil. Med."},{"key":"ref_8","first-page":"e24438","article-title":"Post-COVID-19 Multisystem Inflammatory Syndrome in Children and Adults: What Happens After Discharge?","volume":"14","author":"Loncharich","year":"2022","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jones, O.Y., and McCurdy, D. (2022). Cell Based Treatment of Autoimmune Diseases in Children. Front. Pediatr., 10.","DOI":"10.3389\/fped.2022.855260"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Arnold, D.D., Yalamanoglu, A., and Boyman, O. (2022). Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.888392"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"McMurray, J.C., May, J.W., Cunningham, M.W., and Jones, O.Y. (2020). Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis- A Critical Review of Its Pathogenesis and Treatment. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.626182"},{"key":"ref_12","first-page":"274","article-title":"Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children","volume":"34","author":"Cron","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40272-020-00421-3","article-title":"Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review","volume":"22","author":"Ferrara","year":"2020","journal-title":"Pediatr. Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: A pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis. Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"qyae019","DOI":"10.1093\/ehjimp\/qyae019","article-title":"Serial cardiac magnetic resonance imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis","volume":"2","author":"Francesco","year":"2024","journal-title":"Eur. Heart J. -Imaging Methods Pract."},{"key":"ref_16","first-page":"e3782","article-title":"Anakinra for Recurrent Fevers in Systemic Lupus Erythematosus","volume":"10","author":"Dein","year":"2018","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.2004.025858","article-title":"Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis","volume":"64","author":"Ostendorf","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Norheim, K.B., Harboe, E., G\u00f8ransson, L.G., and Omdal, R. (2012). Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome\u2014A double blind, randomised clinical trial. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030123"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107447","DOI":"10.1016\/j.carpath.2022.107447","article-title":"Cardiac macrophage density in COVID-19 infection: Relationship to myocyte necrosis and acute lung injury","volume":"60","author":"Kundrapu","year":"2022","journal-title":"Cardiovasc. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4049\/jimmunol.173.1.321","article-title":"Epstein-Barr Virus Promotes Human Monocyte Survival and Maturation through a Paracrine Induction of IFN-\u03b1","volume":"173","author":"Lyons","year":"2004","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","article-title":"IL-1 blockade in autoinflammatory syndromes","volume":"65","author":"Jesus","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41584-024-01108-6","article-title":"Time for a new approach to drug development for rare systemic autoinflammatory diseases","volume":"20","author":"Zitoun","year":"2024","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/9\/1146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:06Z","timestamp":1760112126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/11\/9\/1146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["children11091146"],"URL":"https:\/\/doi.org\/10.3390\/children11091146","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}